EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a...
Stay updated with breaking news from David Clair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a...
MINNEAPOLIS, May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets... | May 12, 2023
MINNEAPOLIS, May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31,... | May 3, 2023
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter...
MINNEAPOLIS, May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation today reported its financial results for the third quarter ended March 31, 2023. Third Quarter FY2023 Highlights Third quarter... | May 3, 2023